Arulanandam et al. demonstrate that HER2 positive cancer cells are sensitized to oncolytic rhabdovirus by an antibody-drug conjugate consisting of HER2- targeting trastuzumab linked to the microtubule destabiliser DM1. This study suggests the potential of such combination therapy in the treatment of HER2-positive cancers.
- Rozanne Arulanandam
- Zaid Taha
- Jean-Simon Diallo